Skip to content

US · PDEX · MEDICAL - INSTRUMENTS & SUPPLIES

Pro-Dex, Inc. (PDEX) intrinsic value and stock valuation

$63.00as of 2026-11-21 · Mkt cap 211.68M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Pro-Dex, Inc. DCF and intrinsic value

InvestorsCraft values PDEX with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from PDEX’s statements →

Pro-Dex, Inc. Graham Number

Graham Number: $26.17d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Instruments & Supplies Irvine, CA 92614 pro-dex.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$66.6M+13.8% 5y CAGRd
20112025
Net income
$8.98M+8% 5y CAGRd
20112025
Free cash flow
-$-2.93M
20112025
Total equity
$36.6M+14% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$66.6M$53.8M$46.1M$42M$42M
Operating income$10.7M$7.17M$5.76M$5.12M$5.12M
Net income$8.98M$2.13M$7.07M$4.57M$4.57M
EPSd$2.67M$596.6K$1.94M$1.22M$1.16M
Operating cash flow-$-1.68M$6.2M$5.46M-$-850K-$-850K
Capital expenditure-$-1.25M-$-980K-$-970K-$-1.67M-$-1.67M
Free cash flow-$-2.93M$5.22M$4.49M-$-2.52M-$-2.52M
Total assets$61.2M$52.5M$51.8M$49.1M$49.1M
Total debt$16.6M$13.6M$14.8M$16M$16M
Net debt$16.2M$10.9M$11.9M$15.1M$15.1M
Total equity$36.6M$30.9M$31.6M$25.4M$25.4M
Cash and short-term investments$7.16M$6.85M$4.07M$1.6M$1.6M
Income statement
20252024202320222021
Revenue$66.6M$53.8M$46.1M$42M$42M
Cost of revenue$47.1M$39.3M$33.3M$28.9M$28.9M
Gross profit$19.5M$14.6M$12.8M$13.1M$13.1M
Research and development expenses$3.64M$3.19M$2.8M$2.98M$2.98M
Selling, general and administrative expenses$5.18M$4.19M$4.18M$4.99M$4.99M
Other expenses$0.00$0.00$0.00$40K$40K
Operating expenses$8.82M$7.38M$6.99M$8.01M$8.01M
Cost and expenses$55.9M$46.7M$40.3M$36.9M$36.9M
Interest income$80K$140K$290K$80K$130K
Interest expense$830K$560K$530K$460K$350K
Depreciation and amortization$1.24M$1.16M$860K$730K$730K
Ebitda$14.1M$4.35M$10.8M$6.88M$6.88M
Operating income$10.7M$7.17M$5.76M$5.12M$5.12M
Total other income/expenses, net$1.37M-$-4.54M$3.67M$570K$570K
Income before tax$12.1M$2.63M$9.43M$5.69M$5.69M
Income tax expense$3.08M$510K$2.35M$1.12M$1.12M
Net income$8.98M$2.13M$7.07M$4.57M$4.57M
Weighted average shares outstanding$3.29M$3.5M$3.57M$3.64M$3.8M
Weighted average diluted shares outstanding$3.36M$3.57M$3.64M$3.76M$3.94M
Balance sheet
20252024202320222021
Cash and short-term investments$7.16M$6.85M$4.07M$1.6M$1.6M
Net receivables$17.5M$13.9M$9.95M$15.4M$15.4M
Inventory$22.2M$15.3M$16.2M$12.7M$12.7M
Total current assets$47.3M$36.6M$31M$31.2M$31.2M
Property, plant and equipment, net$1.05M$12.7M$13.2M$13.4M$13.4M
Goodwill and intangible assets$30K$50K$80K$120K$120K
Long-term investments$150K$1.56M$7.52M$4.08M$4.08M
Total non-current assets$13.9M$15.9M$20.8M$17.9M$17.9M
Total assets$61.2M$52.5M$51.8M$49.1M$49.1M
Accounts payable$4.61M$4.51M$2.26M$3.76M$3.76M
Short-term debt$6.65M$4.83M$4.24M$3.66M$3.66M
Deferred revenue$200K$10K$0.00$1.01M$1.01M
Total current liabilities$14.6M$12.9M$9.68M$11.4M$11.4M
Long-term debt$9.93M$8.72M$10.6M$12.3M$12.3M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$9.93M$8.72M$10.6M$12.3M$12.3M
Capital lease obligations$1.18M$1.64M$2.05M$2.43M$2.43M
Total liabilities$24.6M$21.6M$20.2M$23.7M$23.7M
Common stock$700K$3.92M$6.77M$7.68M$7.68M
Retained earnings$35.9M$27M$24.8M$17.8M$17.8M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$36.6M$30.9M$31.6M$25.4M$25.4M
Total investments$6.89M$5.78M$8.65M$4.84M$4.84M
Total debt$16.6M$13.6M$14.8M$16M$16M
Net debt$16.2M$10.9M$11.9M$15.1M$15.1M
Cash flow statement
20252024202320222021
Net income$8.98M$2.13M$7.07M$4.57M$4.57M
Depreciation and amortization$1.24M$1.16M$860K$730K$730K
Stock-based compensation$560K$600K$770K$1.27M$1.27M
Change in working capital-$-10.45M-$-230K$400K-$-6.54M-$-6.54M
Accounts receivable-$-2.55M-$-3.94M$5.43M-$-4.45M-$-4.45M
Inventory-$-6.94M$900K-$-3.49M-$-4.24M-$-4.24M
Accounts payable$180K$2.44M-$-1.15M$1.99M$1.99M
Net cash provided by operating activities-$-1.68M$6.2M$5.46M-$-850K-$-850K
Investments in property, plant and equipment-$-1.25M-$-980K-$-970K-$-1.64M-$-1.64M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-240K-$-2.23M-$-890K-$-1.24M-$-1.24M
Common stock issued$40K$0.00$0.00$0.00$100K
Common stock repurchased-$-3.5M-$-3.5M-$-1.55M-$-1.61M-$-5.54M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-290K-$-4.27M-$-2.49M-$-790K-$-790K
Net change in cash-$-2.21M-$-300K$2.09M-$-2.87M-$-2.87M
Cash at end of period$420K$2.63M$2.94M$850K$850K
Operating cash flow-$-1.68M$6.2M$5.46M-$-850K-$-850K
Capital expenditure-$-1.25M-$-980K-$-970K-$-1.67M-$-1.67M
Free cash flow-$-2.93M$5.22M$4.49M-$-2.52M-$-2.52M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Pro-Dex, Inc.

        Pro-Dex, Inc. focuses on the development and manufacturing of advanced motorized surgical instruments. These sophisticated tools are supplied globally to original equipment manufacturers (OEMs) in the medical device sector. Their product portfolio features versatile, autoclavable (sterilization-friendly) surgical drivers and shavers, available in both battery-powered and electric models, often equipped with multi-functional capabilities. These instruments are primarily employed in orthopedic, thoracic, and craniomaxillofacial surgical procedures. Beyond its core manufacturing, Pro-Dex also offers expert consulting services, covering engineering, quality assurance, and regulatory compliance. Furthermore, the company manufactures and distributes rotary air motors to various industrial clients. Founded in 1978, Pro-Dex, Inc. maintains its corporate headquarters in Irvine, California.

        CEO
        Richard Lee Van Kirk Jr.
        Employees
        181
        Beta
        0.05

        Explore

        Frequently asked questions

        What is the intrinsic value of Pro-Dex, Inc. (PDEX)?

        Pro-Dex, Inc. (PDEX) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is PDEX undervalued?

        PDEX trades at a price of $63.00 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.